Acorda Therapeutics Inc

NASDAQ ACORQ

Data sourced from iex and EODHD
Download Data

Acorda Therapeutics Inc Cash Taxes 1 year YoY Change (%) for the quarter ending September 19, 2024

Acorda Therapeutics Inc Cash Taxes 1 year YoY Change (%) is NA for the quarter ending September 19, 2024. Cash taxes represent the total amount of cash paid for income taxes, including both current and deferred taxes. It is calculated by summing the income tax provision and any non-cash tax-related items. This metric provides insight into the company's cash outflows related to taxes, which can impact its overall cash position and liquidity. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
NASDAQ: ACORQ

Acorda Therapeutics Inc

CEO -
IPO Date Feb. 10, 2006
Location United States
Headquarters 2 Blue Hill Plaza, Pearl River, NY, United States, 10965
Employees 102
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

StockViz Staff

September 19, 2024

Any question? Send us an email